TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7580706
Drug: Decrement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrement of 1 mumol/l of uncategorised unstandardised vitamin E concentration
Study: 2068533
Drug: Soluble interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble interleukin-2 receptors
Study: 6117379
Drug: Oxprenolol SR
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol SR (160-320 mg/day)
Study: 17267931
Drug: Increased support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased support through six weekly visits by a trained advisor
Study: 11885112
Drug: Second-generation anticonvulsants
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation anticonvulsants (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide)
Study: 11885112
Drug: First-generation anticonvulsants
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation anticonvulsants (phenobarbital, phenytoin, valproate)
Study: 30157103
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (20 g of protein, 2 servings daily)
Study: 30157103
Drug: Native whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native whey supplementation (20 g of protein, 2 servings daily)
Study: 25419179
Drug: Intraoperative glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative glucose-insulin-potassium infusion (GIK)
Study: 25419179
Drug: Intraoperative sliding-scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative sliding-scale insulin boluses (BR)
Study: 25419179
Drug: GLP-1 pre-treatment
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 pre-treatment with liraglutide (LG)
Study: 23015652
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels (LH, FSH, testosterone, inhibin B)
Study: 20568977
Drug: iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 400 mgI/ml
Study: 8495260
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise regime of six exercises
Study: 28370210
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment (three-monthly single-dose)
Study: 25675113
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract for 5 months
Study: 19001792
Drug: n-3 PUFA-enriched
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA-enriched fat blend (0.69 g/day)
Study: 17283875
Drug: HES (hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (hydroxyethyl starch 130/0.4, 60 g/L)
Study: 3107495
Drug: Verapamil (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (480 mg)
Study: 28332096
Drug: Paricalcitol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (3 μg)
Study: 18165577
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with ropivacaine (1.5 mg/kg, max 150 mg)
Study: 10786733
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 4% nebulized lignocaine
Study: 8368636
Drug: Vaccine (1,436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (1,436 subjects) - 1.75 mg of formaldehyde‐killed spherules of Coccidioides immitis, administered as three intramuscular injections
Study: 8368636
Drug: Placebo (1,431
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1,431 subjects) - sterile 0.85% NaCl solution, administered as three injections
Study: 3716812
Drug: Triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.25 mg after 1 night of medication
Study: 3716812
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg after 1 night of medication
Study: 3716812
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg after 3 nights of medication
Study: 3716812
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 1 night of medication
Study: 3716812
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 3 nights of medication
Study: 26959612
Drug: Whole-pelvic (WP)
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvic (WP) volumetric-modulated arc therapy (VMAT) at 46.8 Gy in 26 fractions
Study: 26959612
Drug: Prostate-only (PO)
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-only (PO) volumetric-modulated arc therapy (VMAT)
Study: 20093512
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 2.5 mg
Study: 12088808
Drug: Postoperative IV
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative IV morphine
Study: 9484821
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 160 mg t.i.d. for 8 days before each chemotherapy cycle
Study: 8587269
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.55 g/kg/day)
Study: 8587269
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (2 g/kg/day)
Study: 2663900
Drug: Ritalin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin 0.15 mg/kg BID
Study: 2663900
Drug: Ritalin 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin 0.35 mg/kg BID
Study: 2663900
Drug: Ritalin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin (both doses)
Study: 27806919
Drug: Drug-Coated Stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Stent (DCS)
Study: 27898256
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser (LLL) therapy (780 nm laser, dose of 35.0 J/cm2, for 20 sec, thrice a week, for 4 weeks)
Study: 27898256
Drug: Physiotherapeutic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapeutic and Drug Protocol (PDP) (hot packs thrice a day for 15 min, mouth exercises twice a day, myorelaxing and anti-inflammatory drugs)
Study: 8536300
Drug: Apomorphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine administration
Study: 1517428
Drug: Self‐reinforced poly‐L‐lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐reinforced poly‐L‐lactide (SR‐PLLA) screw
Study: 23448581
Drug: Proactive multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive multifactorial intervention (PMI) strategy based on single‐pill amlodipine/atorvastatin (SPAA)
Study: 15159722
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg/day) added to ACEI
Study: 11681653
Drug: Easyhaler (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easyhaler (200 microg/dose of beclomethasone dipropionate)
Study: 11681653
Drug: pMDI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI plus Volumatic spacer (250 microg/dose of beclomethasone dipropionate)
Study: 9773796
Drug: Mean urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean urea reduction ratio (URR) among treatment centers, 64.9%
Study: 9773796
Drug: Free-standing status
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-standing status of treatment centers
Study: 396647
Drug: Iron tablets
Normalized name: Iron 65 MG Oral Tablet [LEADER IRON TABLETS]
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablets (Neo‐Fer) containing 0.20 g ferrous fumarate (60 mg Fe++)
Study: 31680064
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of gonadotrophin
Study: 31680064
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of gonadotrophin (frozen embryo transfer subgroup)
Study: 26422094
Drug: Esomeprazole 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 0.25 mg/kg
Study: 26422094
Drug: Esomeprazole 1
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 1 mg/kg
Study: 23308394
Drug: Grains of
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grains of paradise extract (40 mg)
Study: 22097200
Drug: Qianggan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggan Capsule (QC) for 6 months
Study: 22097200
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (glucurone and compound vitamin B) for 6 months
Study: 16895135
Drug: Johnstone pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnstone pressure splint (JPS) - administered for 30 minutes 3 days per week
Study: 7951099
Drug: Epoetin-alpha 300
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha 300 or 450 iu/kg subcutaneously thrice weekly for 2 weeks
Study: 2085982
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol 3 g
Study: 354147
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (500 mg daily, total dose 30 g)
Study: 354147
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (1,000 mg daily, total dose 60 g)
Study: 27889546
Drug: 2-L PEG-Asc
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG-Asc
Study: 14727149
Drug: Full course
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full course of oral levofloxacin (500 mg q12 h)
Study: 14727149
Drug: Intravenous-to-oral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-to-oral sequential therapy (intravenous ceftriaxone 2 g q24 h with or without clarithromycin 500 mg q12 h followed by oral beta-lactam)
Study: 14727149
Drug: Full course
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full course of oral levofloxacin
Study: 14727149
Drug: Intravenous-to-oral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-to-oral sequential therapy
Study: 11461805
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug (possibly at different dosages)
Study: 11461805
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of the study drug
Study: 11461805
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of the study drug
Study: 9066005
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion in ACEI-treated patients
Study: 9066005
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion in placebo-treated patients
Study: 7526067
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg idrapril
Study: 7526067
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg idrapril
Study: 7526067
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg idrapril
Study: 7526067
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg idrapril (oral)
Study: 7526067
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg captopril
Study: 3443046
Drug: Stepronine-lysine salt
Normalized name: stepronin
DrugBank: Stepronin (DB01423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepronine-lysine salt treatment
Study: 26754182
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the PC 6 acupuncture point for 14 seconds (300 mW, energy density 4 J/cm²)
Study: 23286297
Drug: Optimized acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized acupuncture treatment
Study: 19399583
Drug: Preoperative supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative supplement of carbohydrate and branched-chain amino acid-enriched nutrient mixture
Study: 12529343
Drug: Platinum-based adjuvant
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based adjuvant chemotherapy
Study: 8855176
Drug: Higher dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose, 6 MU three times per week
Study: 8855176
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of interferon treatment for acute hepatitis C
Study: 1891951
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine (PRP-D)
Study: 1891951
Drug: Conjugate vaccine
Normalized name: meningococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate vaccine (PRP-D or HbOC)
Study: 1891951
Drug: Conjugate vaccines
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugate vaccines (PRP-D, HbOC, PRP-T)
Study: 6671926
Drug: Amoxycillin (582
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (582 mg)
Study: 6671926
Drug: Ampicillin from
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin from bacampicillin (800 mg)
Study: 31444999
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg daily
Study: 30196134
Drug: Dose and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and fractionation schedule
Study: 22424025
Drug: Pravastatin (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (concomitant treatment)
Study: 17499999
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 5 mg kg(‐1) after induction of anaesthesia
Study: 15020614
Drug: Fotemustine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustine 100 mg/m2 weekly for 3 weeks
Study: 15020614
Drug: DTIC 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 250 mg/m2/d for 5 consecutive days every 4 weeks
Study: 10075217
Drug: Serologic screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serologic screening and treatment of syphilis
Study: 10075217
Drug: Diagnosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis and treatment of tuberculosis
Study: 2650698
Drug: Eating fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eating fish once or twice a week
Study: 25939436
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone for 21 days in addition to conventional heart failure medication
Study: 23435927
Drug: IncobotulinumtoxinA (Xeomin(®)),
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (Xeomin(®)), ≤ 50 U per eye, flexible doses, flexible injection intervals (minimum of 6 weeks)
Study: 17190733
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (Ca-A)
Study: 9646426
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3 g
Study: 3414406
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg) and hydrochlorothiazide (50 mg) (Moduretic)
Study: 31922432
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (0.2 mg/kg)
Study: 31922432
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1 mg/kg)
Study: 31922432
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (0.2 mg/kg) and IV lidocaine (1 mg/kg)
Study: 31233407
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 μg/kg intravenously)
Study: 26281053
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (1 mg twice daily) via transnasal nebulization for one week
Study: 26281053
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (24 mg QD)
Study: 23374898
Drug: Rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 2.5 mg/day combined with Ezetimibe 10 mg/day (R2.5/E10)
Study: 21474637
Drug: 8-week multidisciplinary
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week multidisciplinary group therapy program consisting of physical exercise and educational program
Study: 18061276
Drug: Pharmacotherapy (PhT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PhT)
Study: 16390499
Drug: Testoderm TTS
Normalized name: Testosterone 5 MG/24 HR Transdermal Patch, Extended Release [TESTODERM TTS]
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testoderm TTS body patch (5 mg/day, n = 20)
Study: 16390499
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (n = 19)
Study: 16390499
Drug: Testoderm TTS
Normalized name: Testosterone 5 MG/24 HR Transdermal Patch, Extended Release [TESTODERM TTS]
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testoderm TTS body patch (5 mg/day, n = 20) and Placebo patch (n = 19)
Study: 14606111
Drug: Fluconazole (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (low dosage) prevention group
Study: 10929446
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram alfacalcidol plus 5000 mg calcium (group A)
Study: 10929446
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D plus 500 mg calcium (group B)
Study: 1563531
Drug: tolrestat 200
Normalized name: tolrestat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolrestat 200 mg once daily for 6 months
Study: 4003919
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (theophylline + salbutamol)
Study: 27565426
Drug: Antrodia cinnamomea
Normalized name: Antrodia cinnamomea fruiting body
DrugBank: Taiwanofungus camphoratus fruiting body (DB19272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antrodia cinnamomea (AC) 20 ml twice daily for 30 days
Study: 25438877
Drug: Financial reward
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial reward for each accepted antipsychotic medication depot (M4M)
Study: 25438877
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual without financial rewards
Study: 11809987
Drug: Nottingham Extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nottingham Extended Activities of Daily Living index (NEADL)
Study: 10609815
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 75 mg twice daily
Study: 29446445
Drug: Lenograstim 5
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim 5 micro g/kg
Study: 29446445
Drug: Biosimilar filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biosimilar filgrastim 10 micro g/kg
Study: 27098429
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with BCNU (or busulfan) and thiotepa followed by autologous stem cell transplantation (HCT‐ASCT)
Study: 27098429
Drug: Conventional‐dose immuno
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional‐dose immuno chemotherapy with rituximab 375 mg/m(2) (d0), dexamethasone 40 mg/d (d1‐3), etoposide 100 mg/m(2)/d (d1‐3), ifosfamide 1500 mg/m(2)/d (d1‐3) and carboplatin 300 mg/m(2) (d1) (R‐DeVIC)
Study: 24465425
Drug: Progesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (300 mg daily)
Study: 16107306
Drug: aceclofenac-loaded soft
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aceclofenac-loaded soft capsule (100mg)
Study: 16107306
Drug: conventional aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional aceclofenac tablet (100mg)
Study: 7003573
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release papaverine preparation
Study: 25885258
Drug: Wrist acceleration
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist acceleration measurement pre- and post-treatment
Study: 24052565
Drug: 2g pralidoxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g pralidoxime over 20 min, followed by an infusion of 0.5 g/h
Study: 20406523
Drug: Waiting list/delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list/delayed treatment control (WL/DTC)